Perioperative NP137 with FOLFIRINOX for operable pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study tests a new drug (NP137) combined with standard chemotherapy before and after surgery for pancreatic cancer that can be removed. The goal is to see if adding NP137 helps reduce the chance of the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your pancreatic cancer must be removable with surgery and have not spread to other organs.
- You must be willing to have a biopsy (tissue sample) as part of the study.
- You must not have had prior chemotherapy, radiation, or surgery for pancreatic cancer.
- You must be 18 or older, with a performance status of 0 or 1 (meaning you are fairly active and able to care for yourself).
- Your heart, liver, and kidney function must be adequate, and you must not be pregnant or breastfeeding.
- You must not have certain conditions like active infections, untreated hepatitis, HIV, or serious heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether FOLFIRINOX given after pancreatic surgery can lower the chance the cancer comes back. It focuses on people with pancreatic ductal adenocarcinoma who had their tumor completely removed and have no spread to distant organs.
This trial tests a combination of chemotherapy (mFOLFIRINOX) and radiation therapy for people with advanced pancreatic cancer that has stopped responding to chemotherapy and whose CA19-9 tumor marker levels are normal. The goal is to see if this approach can help when standard treatments are no longer working.
This trial tests a combination of standard chemotherapy, MRI-guided radiation, and surgery for people with locally advanced pancreatic cancer that might be removable. The goal is to see if this approach can make more tumors resectable.
This trial uses a special gene test on fluid taken from an endoscopic ultrasound (EUS) biopsy to help choose chemotherapy before surgery for pancreas cancer. It aims to see if this approach improves outcomes by matching treatment to the tumor’s RNA pattern.
This trial tests a combination of chemotherapy drugs (liposomal irinotecan with fluorouracil, leucovorin, and oxaliplatin) given before and after surgery for pancreatic cancer that can be fully removed. It aims to see if this approach improves outcomes for patients with stage I or II disease.
This Phase 2 study looks at different types (subtypes) of pancreatic tumors in people treated with FOLFIRINOX, a chemotherapy. It requires tumor biopsies before and after treatment to see how the tumor changes, which may help doctors better match treatments in the future.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.